Pathologic response rate after concomitant neo-adjuvant radiotherapy and chemotherapy for adenocarcinoma of the uterine cervix: A retrospective multicentric study

International Journal of Gynecological Cancer

Volumn 20, Issue 5, 2010, Pages 815-820

  Poujade, Olivier ^a   Morice, Philippe ^b   Rouzier, Roman ^c   Madelenat, Patrick ^d   Lecuru, Fabrice ^e,f,g   Muray, Jean Michel ^h   Mathevet, Patrice ⁱ   Alran, Séverine ^j   Salmon, Remy J ^j   Reyal, Fabien ^j  

^a BEAUJON HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Service de Gynécologie Obstétrique   (United Kingdom)

^d BICHAT HOSPITAL   (France)

^e Service de Chirurgie Gynécologique et Cancérologique   (France)

^f CH Rene Dubos   (France)

^g INSERM   (France)

^h CENTRE HOSPITALIER RENÉ DUBOS   (France)

ⁱ Hospices Civils de Lyon   (France)

^j INSTITUT CURIE   (France)

more..

Author keywords

Cervical adenocarcinoma; Chemoradiotherapy; Neoadjuvant; Surgery

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; MITOMYCIN; PACLITAXEL; VINDESINE;

ADENOCARCINOMA OF THE UTERINE CERVIX; ADENOCARCINOMA OF THE UTERUS CERVIX; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL EVALUATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FRANCE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MUCINOUS CARCINOMA; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 77956821072     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181df7406     Document Type: Article

References (25)

1. Smith HO, Tiffany MF, Qualls CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United StatesVa 24-year population based study. Gynecol Oncol. 2000;78:97Y105.
2. Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83: 18Y29.
3. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22:872Y880.
4. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339Y1348.
5. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144Y1153.
6. Chapman JD, Engelhardt EL, Stobbe CC, et al. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol. 1998;46:229Y237.
7. Kjorstad KE. Adenocarcinoma of the uterine cervix. Gynecol Oncol. 1977;5:219Y223.
8. Hopkins MP, Morley GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol. 1991;77:912Y917.
9. Kurman JR, Norris HJ, Wilkinson E. Tumors of the cervix, vagina, and vulva. In: Rosai J, Sobin LH, eds. Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology; 1992.
10. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumours in the female pelvis. Int J Gynaecol Obstet. 1965;3:206Y207.
11. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet. 2001;357:1490Y1493.
12. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage IbYIIa cervical cancer. Lancet. 1997;350:535Y540.
13. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340: 1137Y1143.
14. Costa MJ, McIlnay KR, Trelford J. Cervical carcinoma with glandular differentiation: Histological evaluation predicts disease recurrence in clinical stage I or II patients. Hum Pathol. 1995;26:829Y837.
15. Ishikawa H, Nakanishi T, Inoue T, et al. Prognostic factors of adenocarcinoma of the uterine cervix. Gynecol Oncol. 1999; 73:42Y46.
16. Liu MT, Hsu JC, Liu WS, et al. Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy. Eur J Cancer Care. 2008;17:174Y181.
17. Suzuki Y, Nakano T, Kato S, et al. Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: P53 status has a strong impact on prognosis. Int J Radiat Oncol Biol Phys. 2004;60:231Y236.
18. Alfsen GC, Kristensen GB, Skovlund E, et al. Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: A population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix. Cancer. 2001;92:2471Y2483.
19. Alfsen GC, ReedW, Sandstad B, et al. The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: An immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma. Cancer. 2003;98:1880Y1889.
20. Kaku T, Sonoda K, Kamura T, et al. The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. Clin Cancer Res. 1999;5:1449Y1453.
21. Baalbergen A, Ewing-Graham PC, Hop WC, et al. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol. 2004;92:262Y267.
22. Atahan IL, Onal C, Ozyar E, et al. Long-term outcome and prognostic factors in patients with cervical carcinoma: A retrospective study. Int J Gynecol Cancer. 2008;18:386.
23. Irie T, Kigawa J, Minagawa Y, et al. Prognosis and clinicopathological characteristics of IbYIIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol. 2000;26:464Y467.
24. Herr D, König J, Heilmann V, et al. Prognostic impact of satellite-lymphovascular space involvement in early-stage cervical cancer. Ann Surg Oncol. 2009;16:128Y132.
25. Raju K, Kjorstad K, Abeler V. Prognostic factors in the treatment of stage IB adenocarcinoma of the cervix. Int J Gynecol Cancer. 1991;1:69Y74.